Dr. Preston has been awarded a $774K award from the U.S. Army Medical Research Acquisition Activity for his study: “PSA level during midlife and undiagnosed prostate cancer at autopsy: Understanding tumor biology and racial disparities.”
The study aims to develop smarter screening strategies to accurately identify men at risk for developing advanced prostate cancer while minimizing harms by testing mid-life PSA levels. The study will obtain blood from autopsies of black and white men to assess how PSA in midlife relates to pre-diagnosis natural history of prostate cancer and to determine when racial differences manifest in the natural history of prostate cancer.
Mark Preston, MD, MPH
Mark A. Preston, MD, is a urologic surgeon at Brigham and Women’s Hospital and assistant professor of surgery at Harvard Medical School. Dr. Preston received his medical degree from the University of Ottawa in Canada, where he also completed his residency training in Urology. He completed a three-year accredited fellowship in Urologic Oncology at Massachusetts General Hospital including a master of public health from the Harvard T.H. Chan School of Public Health with a concentration in clinical effectiveness. He is board certified in Urology.
Dr. Preston’s clinical interests include urologic oncology (bladder, kidney, prostate and testicular cancer) and minimally invasive surgery. Dr. Preston’s research focuses on the epidemiology of prostate and kidney cancer risk with an emphasis on predictive biomarkers and pharmacoepidemiology.